Trials / Completed
CompletedNCT03876106
A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions
A Phase 1, Open-Label, Dose Escalation Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Lutris Pharma Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase 1, multicenter study is to evaluate the safety, tolerability and preliminary efficacy of LUT014 in adult metastatic colorectal cancer patients with EGFR Inhibitor induced acneiform lesions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LUT014 | Topical |
Timeline
- Start date
- 2019-08-21
- Primary completion
- 2020-07-09
- Completion
- 2020-11-18
- First posted
- 2019-03-15
- Last updated
- 2022-04-06
Locations
6 sites across 2 countries: United States, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03876106. Inclusion in this directory is not an endorsement.